Qiagen AdnaTest ProstateCancerPanel AR-V7 and LungCancer Kits
Qiagen this week launched the AdnaTest ProstateCancerPanel AR-V7 and AdnaTest LungCancer kits at the American Association for Cancer Research annual meeting.
AdnaTest ProstateCancerPanel AR-V7 detects the androgen receptor splice variant 7 in circulating tumor cells (CTCs) of prostate tumor origin isolated from blood samples to investigate potential resistance to drugs for advanced prostate cancer. With an exclusive worldwide license from Johns Hopkins University for nucleic acid detection of the AR-V7 biomarker for diagnostic use, Qiagen is now launching the test for research use.
AdnaTest LungCancer provides insights into the molecular mechanisms of lung cancer through highly specific selection of CTCs, including stem cell-like cells implicated in cancer growth and epithelial-mesenchymal transition, an important marker of cancer therapy resistance. A proprietary set of antibodies provides sensitive detection of lung cancer-associated targets through reverse-transcriptase PCR, and the open system enables users to add targets of interest.